Home » Health » Wellington man Finlay Thompson on weight loss drug Wegovy after Medsafe approval

Wellington man Finlay Thompson on weight loss drug Wegovy after Medsafe approval

Weight-Loss Drug “Life-Changing” for New Zealander

Wegovy now available in New Zealand pharmacies

For **Finlay Thompson**, the arrival of Wegovy in New Zealand pharmacies marks a turning point. Having experienced significant weight loss through Ozempic in a clinical trial, he is eager to resume treatment and regain a more active lifestyle.

Dramatic Results During Clinical Trial

**Thompson** participated in a strictly controlled clinical trial using Ozempic, during which he shed 30kg. According to **Thompson**, the medication’s impact was immediate, with weight loss starting right away.

Finlay Thompson lost 30kg taking part in a trial of the drug Ozempic. He is pictured in his Wellington office (right), and in April 2023 prior to starting the trial (left). Photo / Mark Mitchell.

During the trial, **Thompson’s** weight decreased from 138kg to 108kg. The medication curbed his appetite and created a sensation of fullness. He told the *Herald* that it was kind of astonishing how quickly it has an effect.

After the trial ended, **Thompson** managed to maintain his weight at around 100kg for three months. However, he began to regain weight, adding 15kg back.

Wellington man Finlay Thompson on weight loss drug Wegovy after Medsafe approval
Finlay Thompson’s Ozempic ‘pen’, which is administered weekly. Photo / Supplied

Accessing Wegovy

Developed by Novo Nordisk Pharmaceuticals, Wegovy’s availability in New Zealand excites **Thompson**. He is ready to start using it. **Thompson** said, “It’s been life-changing for me personally.”

He anticipates saving around $300 monthly on food costs, which offsets the $489 monthly cost of the medication.

Broader Implications

While he believes it will help many New Zealanders, **Thompson** acknowledges the price could be prohibitive for some. He expressed hope for future subsidies.

Finlay Thompson's view on the weight loss drug
**Finlay Thompson** said the weight loss drug is “life-changing”. Photo / Mark Mitchell

Reportedly, vision loss is a possible adverse effect for some semaglutide users. Novo Nordisk stated that patient safety is paramount, and adverse event reports are taken seriously. As of November 2023, The American Academy of Ophthalmology has also addressed vision-related concerns regarding semaglutides AAO, 2023.

The company stated that over 52,000 patients were exposed to semaglutide in clinical development programs, with over 33 million patient years of post-marketing use. Label updates on June 6 included this condition with a frequency of “very rare,” meaning it may affect up to one in 10,000 people.

**Thompson** said, I was getting quite depressed actually, I was watching my weight continue to increase.

He now cycles to work and enjoys weekend walks and swims. Everything is a little bit easier when you’re a bit smaller.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.